Immunotherapy-based targeting of MSLN <sup>+</sup> activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosisTakahiro Nishio, Tatiana Kisseleva|Proceedings of the National Academy of Sciences|2021Cited by 29